pipette
ESEspañol

Targeting ZIP12-mediated Zn 2+ signaling as a treatment for pulmonary hypertension

Lan Zhao, Lan Zhao, Stephanie Hopley, Chien-Nien Chen, Iyobel Kibreab, Chongyang Xie, Nicoleta Baxan, Ali Ashek, Adam Fellows, Daria S. Kostyunina, Adam Fellows, Daria S. Kostyunina, Eduardo Oliver, Lei Wang, Shu Ning, Guy A. Rutter, Richard P. Butt, Paul Hamblin, Martin R. Wilkins, Paul Hamblin, Martin R. Wilkins

Peer-reviewed journalBold claims, read criticallyReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
We developed a humanized anti-ZIP12 monoclonal antibody, APL-9796, that normalized intracellular Zn 2+ concentration, suppressed proliferation in fibroblasts derived from patients with PAH and PDGF-stimulated PASMCs, and reduced PDGF-induced cytoskeletal remodeling in PASMCs and contractility in PASMCs and engineered pulmonary artery tissues.

Appeared: Friday, October 23. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.aee0680